Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2378]

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy...

Prof Barbara Eichhorst - University of Cologne, Cologne, Germany

Time-limited venetoclax-obinutuzumab +/- ibrutnib surpasses chemoimmunotherapy in frontline chronic lymphocytic leukaemia ( Prof Barbara Eichhorst - University of Cologne, Cologne, Germany )

Quizartinib advances overall survival in acute myeloid leukaemia patients

Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA

Quizartinib advances overall survival in acute myeloid leukaemia patients ( Dr Harry Erba - The Duke Cancer Institute, North Carolina, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

The abscopal effect of radiotherapy and nivolumab in relapsed or refractory...

Dr Paul Bröckelmann - University of Cologne, Cologne, Germany

$The abscopal effect of radiotherapy and nivolumab in relapsed or refractory Hodgkin lymphoma ( Dr Paul Bröckelmann - University of Cologne, Cologne, Germany )$

Lack of access to new cancer medicines in LMICs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

Lack of access to new cancer medicines in LMICs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Spotlight on global cancer control at ASCO 2022

Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM

Spotlight on global cancer control at ASCO 2022 ( Prof Eduardo Cazap - Editor-in-Chief, ecancer and SLACOM )

UICC announces global coalition to increase access to essential cancer...

Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries ( Dr Cary Adams - Chief Executive Officer, Union for International Cancer Control )

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can...

Dr Timothy J. Whelan - McMaster University, Ontario, Canada

Luminal A-type breast cancer patients with low levels of the Ki67 biomarker can avoid outcomes related to radiotherapy ( Dr Timothy J. Whelan - McMaster University, Ontario, Canada )

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for...

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

Biomarker analysis of the NeoALTTO trial provides oncofertility insight for younger breast cancer patients ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

ASCO 2022: Breast cancer highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

ASCO 2022: Breast cancer highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA...

Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA

Updated data from the Phase 1/2 MajesTEC-1 study evaluating teclistamab, a BCMA x CD3 bispecific antibody ( Dr Ajay Nooka - Winship Cancer Institute of Emory University, Georgia, USA )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

More from ecancer